Published TCIMAIL newest issue No.201
Maximum quantity allowed is 999
Please select the quantity
CAS RN: 132539-06-1 | Product Number: O0393
Olanzapine
×
Purity: >98.0%(GC)(T)
Synonyms:
- 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine
Product Documents:
| Size | Unit Price | Belgium | Japan* | Quantity |
Shipping Information
|
|---|---|---|---|---|---|
| 1G |
€ 55,00
|
3 | 27 |
|
|
| 5G |
€ 175,00
|
Contact Us | ≥60 |
|
* Stock available in Belgium: Shipment on the same day
* Stock available in Japan: Please check the Shipping Simulation for estimated shipments. (excludes regulated items and dry ice shipments)
| Product Number | O0393 |
Purity / Analysis Method 
|
>98.0%(GC)(T) |
| Molecular Formula / Molecular Weight | C__1__7H__2__0N__4S = 312.44 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature
|
Refrigerated (0-10°C) |
| Condition to Avoid | Heat Sensitive |
| Packaging and Container
|
1G-Glass Bottle with Plastic Insert (View image) |
| CAS RN | 132539-06-1 |
| Reaxys Registry Number | 7655141 |
| PubChem Substance ID | 160871343 |
| Merck Index (14) | 6822 |
| MDL Number | MFCD00866702 |
Specifications
| Appearance | Light yellow to Amber to Dark green powder to crystal |
| Purity(GC) | min. 98.0 % |
| Purity(Nonaqueous Titration) | min. 98.0 % |
Properties (reference)
| Melting Point | 194 °C(dec.) |
| Solubility in water | Insoluble |
GHS
| Pictogram |
|
| Signal Word | Danger |
| Hazard Statements | H301 : Toxic if swallowed. H315 : Causes skin irritation. H319 : Causes serious eye irritation. H413 : May cause long lasting harmful effects to aquatic life. |
| Precautionary Statements | P501 : Dispose of contents/ container to an approved waste disposal plant. P273 : Avoid release to the environment. P264 : Wash skin thoroughly after handling. P280 : Wear protective gloves/ eye protection/ face protection. P337 + P313 : If eye irritation persists: Get medical advice/ attention. P301 + P310 + P330 : IF SWALLOWED: Immediately call a POISON CENTER/doctor. Rinse mouth. |
Related Laws:
| RTECS# | XJ9007750 |
Transport Information:
| UN Number | UN2811 |
| Class | 6.1 |
| Packing Group | III |
| HS Number | 2934999090 |
Application
Bone research
References
- Atypical antipsychotics induce human osteoblasts apoptosis via Wnt/β-catenin signaling
- Effects of Olanzapine on Bone Mineral Density, Glucose, and Lipid Metabolism in Schizophrenia Patients
Application
Olanzapine: A Multi-Acting Receptor Targeted Antipsychotic (MARTA)
Olanzapine is known as a multi-acting receptor targeted antipsychotic (MARTA), such as clozapine [C2547] and quetiapine [Q0092]. Olanzapine has greater affinity for serotonin 5-HT2A and dopamine D2 receptors. Furthermore, olanzapine has various affinities for multiple receptors, including serotonin 5-HT2C, 5-HT6 receptors, dopamine D1-4, histamine H1, and adrenergic α1 receptors. In addition, olanzapine has moderate affinity binding for serotonin 5HT3 and muscarinic M1-5. While, olanzapine binds weakly to GABAA, benzodiazepine (BZD), and β-adrenergic receptors. The precise mechanism of action is unknown, but olanzapine is used as a thienobenzodiazepine atypical antipsychotic.
Recently, it is reported that the use of olanzapine combined with a 5-HT3 receptor antagonist, a neurokinin1 (NK1) receptor antagonist and dexamethasone [D1961] has improved the control of acute chemotherapy-induced nausea and vomiting. (The product is for research purpose only.)
Recently, it is reported that the use of olanzapine combined with a 5-HT3 receptor antagonist, a neurokinin1 (NK1) receptor antagonist and dexamethasone [D1961] has improved the control of acute chemotherapy-induced nausea and vomiting. (The product is for research purpose only.)
References
- Radioreceptor binding profile of the atypical antipsychotic olanzapine
- Binding of antipsychotic drugs to human brain receptors - focus on newer generation compounds
- 5-HT2A and D2 receptor blockade increases cortical DA release via 5-HT1A receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release
- Olanzapine: An updated review of its use in the management of schizophrenia
- Management of chemotherapy-induced nausea, vomiting, oral mucositis, and diarrhea
- Pharmacokinetics and tissue distribution of olanzapine in rats
- Development of a stability-indicating HPLC method for simultaneous determination of olanzapine and fluoxetine in combined dosage forms
PubMed Literature
Documents
Product Articles
Product Documents (Note: Some products will not have analytical charts available.)
Enter TCI Product Number
Enter KISHIDA Product Number
4-5 alphanumeric characters before the hyphen
7 alphanumeric characters
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
• The requested SDS is not available.
Specifications
The requested specifications are not available.
Please Contact Us for more information.
The requested specifications are not available.
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Incorrect Lot Number. Please input only the 7 alphanumeric characters.
• Please check that the lot number you have entered is correct. It is 4-5 alphanumeric characters before the hyphen. In particular, please check O (letter) or 0 (number) and I (letter) or 1 (number).
• If your information is correct and you are still not able to view the requested certificates, Please Contact Us for more information.
• Please check that the lot number you have entered is correct. It is 7 alphanumeric characters. In particular, please check O (letter) or 0 (number) and I (letter) or 1 (number).
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Incorrect Lot Number. Please input only the 7 alphanumeric characters.
The requested analytical chart is not available. Sorry for the inconvenience.